

What is claimed is:

- Sub A.1
- 10
- 15
- 20
- 25
- 30
- 35
1. A method of detecting antibodies in a solution comprising:
 - a.) contacting the solution with an antigen-coated surface of a sensor chip under conditions that permit anti-antigen antibodies to bind to the antigen coating;
 - b.) detecting the change in surface plasmon resonance signal of the sensor chip resulting from the anti-antigen antibodies binding to the antigen coating.
 2. The method of claim 1, wherein the antigen is a glycolipid.
 3. The method of claim 1, wherein the anti-antigen antibodies are anti-glycolipid antibodies.
 4. The method of claim 1, wherein the antigen is a ganglioside and wherein the antibody is an anti-ganglioside antibody.
 5. The method of claim 3, wherein the solution contains anti-glycolipid antibodies that bind to the glycolipid-coated surface of the sensor chip and alter the surface plasmon resonance.
 - 3 6. The method of claim 1, wherein a control surface plasmon resonance value is subtracted from the surface plasmon resonance signal.
 - 4 7. The method of claim 3, wherein the control surface plasmon resonance value comprises the signal detected from the surface of the sensor chip coated with a selected control antigen, wherein the chip is also

alternatively exposed to the solution being evaluated for anti-antigen antibodies.

5 8. The method of ~~claim~~ 7, wherein the control antigen is a glycolipid. ~~83~~

Sub A37
9. ~~The method of claim 8, wherein the control antigen is Ganglioside GM2.~~

10 ⁶ 10. The method of claim 1, wherein the surface plasmon resonance signal is detected from the surface of the sensor chip coated with ganglioside GM1.

1 11. The method of claim 1, wherein the sensor chip comprises a glass slide coated with a gold film covalently linked to a methyl dextran layer.

8 ~~12~~. The method of claim 1, wherein the surface plasmon resonance signal is detected using an optical detector.

20 13. The method of ~~claim~~ 1, wherein the solution is human blood or a derivative of human blood. ~~83~~

9 14. The method of claim 1, wherein the solution is human sera.

15. The method of ~~claim~~ 3, wherein the anti-glycolipid antibody is an Immunoglobulin G.

30 16. The method of claim 3, wherein the anti-glycolipid antibody is an Immunoglobulin M. ~~83~~

17. The method of claim 15 or 16, wherein the anti-glycolipid antibody is an anti-ganglioside antibody.

35 18. The method of claim 16 or 17, wherein the antibody is

human.

- 5 19. A method of determining the anti-glycolipid antibody isotype present in the solution comprising the method of claim 2 wherein the tested solution is washed from the surface of the sensor chip and a second solution containing a secondary antibody is introduced to the surface.

- 10 *Sub A4* 20. A method of increasing the optical signal size of claim 1, comprising washing the tested solution from the surface of the sensor chip and applying a second solution containing the secondary antibody to the surface.

- 15 21. The method of claim 19, wherein the secondary antibody is an anti-Immunoglobulin G.

- 20 22. The method of claim 19, wherein the secondary antibody is an anti-Immunoglobulin M.

23. The method of claim 1, wherein the method is used to diagnose a disease in a subject.

- 25 24. The method of claim 6, wherein the method is used to quantitate levels of antibodies in a subject.

25. The method of claim 23, wherein the disease is neurological.

- 30 *Sub A5* 26. The method of claim 23, wherein the disease is Guillian-Barré syndrome, motor neuropathy, peripheral neuropathy or an autoimmune neuropathy.

35 *add*